|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.21 USD | +0.92% |
|
-0.11% | +7.53% |
| Jan. 16 | Guggenheim Adjusts Price Target on Incyte to $130 From $125, Maintains Buy Rating | MT |
| Jan. 15 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Oncology and Dermatology Pharmaceutical Products | 2.67B | 2.99B | 3.39B | 3.7B | 4.24B | |||||
Total Assets | 3.56B | 4.93B | 5.84B | 6.78B | 5.44B | |||||
Interest Expense | -2.17M | -1.91M | -2.67M | -2.55M | -2.28M | |||||
Income Tax Expense | 63.48M | -378M | 188M | 237M | 284M | |||||
CAPEX | -187M | -181M | -77.83M | -32.49M | -86.26M | |||||
EBT | -232M | 570M | 529M | 834M | 317M | |||||
D&A | 53.71M | 60.54M | 67.86M | 82.66M | 89.25M | |||||
Operating Income | -264M | 586M | 579M | 621M | 61.37M | |||||
Net Income | -296M | 949M | 341M | 598M | 32.62M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 2.6B | 2.9B | 3.2B | 3.5B | 4B | |||||
Total Assets | 337M | 434M | 442M | 432M | 474M | |||||
Europe | 105M | 124M | 147M | - | 260M | |||||
Total Assets | 218M | 287M | 296M | 314M | - | |||||
Total Assets | 4.7M | 2.9M | 1.5M | 4.8M | - | |||||
Other Countries | - | - | - | - | 6.2M | |||||
Total Assets | - | - | - | - | 11.7M | |||||
Europe and Japan | - | - | - | 179M | - | |||||
Total Assets | - | - | - | - | 278M |
- Stock Market
- Equities
- INCY Stock
- Financials Incyte Corporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
